Here you will find current and archived press releases, listings of upcoming events, and news coverage about the company and some of its projects and initiatives.

 

 

IntegraGen and BIOASTER sign a partnership agreement in genomics and transcriptomics

IntegraGen and BIOASTER have been collaborating for several years in the context of genomic and transcriptomic analyses. Driven by a desire to strengthen this relationship further, the two entities have entered into a long-term partnership agreement (Master Research Service Agreement). This agreement will facilitate and accelerate exchanges between (…)  » 

Assises de Génétique à Rennes

Rendez-nous visite à Rennes lors des prochaines Assises de Génétique qui auront lieu du 1er au 4 février 2022. C’est sur le stand n°20 que nous vous accueillerons avec le plus grand des plaisirs.

Les prises de rendez-vous et inscriptions à notre atelier-déjeuner “Après l’ère du séquençage ciblé, les solutions (…)  » 

Interview with CEO Bernard Courtieu

Bernard Courtieu CEO OncoDNA

Ditsa Keren is a technology blogger and entrepreneur with a strong passion for biology, ecology and the environment. She spoke to our CEO Bernard Courtieu to hear about the latest advancements in precision medicine and the promise we bring to oncology physicians and researchers.

Discover the entire interview on (…)  » 

New NGS solution for cancer research

OncoXPLORE, a comprehensive cancer gene panel test for the exploration of solid tumors

On the occasion of the World Cancer Research Day, OncoDNA proudly announces the launch of its latest genomic solution for cancer research, OncoXPLORE. OncoDNA has long been a strong supporter of cancer research. Through a (…)  » 

New Look. New Portfolio. New Opportunities.

Outsmart molecular complexity - OncoDNA group
Following its acquisition by OncoDNA, IntegraGen has been given a brand new look and is ready to take on new projects in the fields of cancer and genetic diseases.

Since the successful takeover in November 2020, IntegraGen has been working hand in hand with OncoDNA (…)  »